目的:评估肺炎支原体肺炎(MPP)临床路径的实施效果。方法采用回顾性研究方法,分析并比较采用临床路径治疗的145例和非临床路径治疗的45例MPP患儿在住院时间、住院费用、治愈率等方面的差异,并探讨临床路径的变异情况。结果临床路径组的住院时间为9 d(6~10 d),短于非临床路径组的10 d(7~12.5 d),差异有统计学意义(P=0.003);治愈率93.8%,高于非临床路径组的84.4%,差异有统计学意义(P=0.043);住院费用为4696.5元(3608.3~5677.6元),高于非临床路径组的3175.3元(2490.8~4585.0元),差异有统计学意义(P<0.001)。临床路径变异率48.3%(70/145)。结论实施MPP临床路径可提高治愈率,缩短住院时间,但该路径在临床实施过程中变异率较高,仍需加以完善并推广使用。%Objective To investigate the efficacy of the clinical pathway introduced in children with Mycoplasma pneu-moniae pneumonia (MMP). Methods Based on a retrospective study, the length of hospital stay, hospital expenses and curative rate were compared between 145 MMP patients managed according to clinical pathway and other 45 MMP patients. The causes of variation were analyzed in the clinical pathway group as well. Results The length of hospital stay in clinical pathway group [9 (6~10) days] was significantly shorter than that in the control group [10 (7-12.5) days] (P=0.003). The curative rate (93.8%) was significantly higher than that in the control group (84.4%) (P=0.043). The hospital expenses [4 696.5 (3 608.3-5 677.6) CNY] was significantly higher than that in the control group [3175.3 (2490.8-4585.0) CNY] (P<0.001). The variation rate of clinical pathway was 48.3%(70/145 cases) in clinical pathway group. Conclusions The curative rate is improved and the length of hospital stay is shortened after the clinical pathway is introduced in MMP children. However, there is a high variation rate in the clinical pathway. It is necessary to optimize the clinical pathway before it is adapted in clinic.
展开▼